Pitfalls and Profits: How to Find the Right Genomics Stocks

Trends in health care can turn into investment opportunities quickly. [Turn Your Images On] [Pitfalls and Profits: How to Find the Right Genomics Stocks]( [Turn Your Images On] [Michael Carr, Chief Market Technician]( Trends in health care can become powerful investment tailwinds. Genomics is a good example of this. Simply put, genomics explores how genes affect us. Now, there’s obviously much more to it than that. It’s a complex technology with almost unimaginable implications. We can think of genomics like a tailor making a suit that fits you perfectly. In medicine, doctors can use information about your genes to choose medicines and treatments that work best for you. For example, if two people have the same kind of sickness, the best medicine for one person might not be ideal for the other because their genes are different. This can be especially important in treating serious diseases like cancer. By studying the genes in cancer cells, doctors can find specific ways to attack these cells without harming the healthy ones. It's like finding the weak spot of an enemy so you can defeat it more effectively. This same idea can be applied to early detection. GRAIL Discovered Genomics’ Potential Researchers know that cancer cells often release tiny bits of their DNA into the blood. By taking a blood sample and using genomics to read the DNA in it, doctors can spot these cancerous bits. It's like finding a fingerprint at a crime scene that tells you who the rule breaker is. This means genomics can help figure out exactly what type of cancer is developing even before it causes any symptoms. So it's like knowing exactly what kind of trouble the offender is likely to cause, even before they do it. This isn’t just a theory. Biotech company GRAIL offers the Galleri test, which can detect a signal shared by over 50 types of cancer. The company [claims]( this test has 99.5% specificity. It can predict the cancer signal origin with high accuracy to help doctors treat the disease. The company [believes]( the test should be part of an annual exam for many people. And this could be profitable for both GRAIL and its investors. In fact, GRAIL has been an interesting case study for anyone interested in biotech investing… --------------------------------------------------------------- [Turn Your Images On]( [“IMPERIUM”: The #1 Investment of the 2020s]( Could the technology behind this [odd-looking machine]( really be the most transformative innovation in history? Experts are screaming “YES”! Elon Musk calls it “amazing…” A former Apple CEO says “[it will] have a far bigger impact on humanity than the Internet”… While a Harvard Ph.D. says it will “[surpass] the space, atomic, and electronic revolutions in its significance.” It’s a technology I call “Imperium.” [And it’s about to spark the biggest investment mega trend in history … with one small Silicon Valley company at the center of it all. Want the details? Then click here now…]( --------------------------------------------------------------- Making Sense of ILMN Illumina Inc. (Nasdaq: ILMN) [created]( GRAIL in 2016 with a spinoff that allowed it to aggressively pursue funding for the company’s innovative technology. In 2020, Illumina [decided]( to buy GRAIL back for $8 billion. Regulators in the U.S. and EU immediately [objected]( to the deal. It seems obvious why Illumina would want to own GRAIL. The work of GRAIL, supported by Illumina's technology, represents a significant step toward personalized medicine. By detecting cancer early through genomics, treatments can be more targeted and maybe even more effective. Illumina could then extend this concept to help detect other diseases. However, regulators are worried that Illumina could use GRAIL’s cancer test as a cash cow to boost its own profits instead of pouring that cash back into research and development for those new products. Regulators often make this claim and companies respond by going to court. The courts often side with the company recognizing that management will make the best use of corporate resources. Nonetheless, Illumina's history with GRAIL shows how companies are applying advancements in genomic technology to real-world challenges like cancer detection. It also illustrates the interplay between technological innovation, commercial interests and regulatory oversight in the rapidly evolving field of genomics. It’s a challenging story for investors to make sense of. That’s why I turn to experts like my friend Adam O’Dell to help me identify opportunities in the biotech field with clarity. Adam and his team study and track cutting-edge trends in the market that no one else sees and use the Green Zone Power Ratings system to uncover the strongest stock investments to grow your portfolio. And using that system shows that ILMN is one of the [highest-risk stocks]( out there with a 0 out of 100 rating! One of the most promising plays [he’s discovered]( is an artificial intelligence company treating infectious diseases using genomics. To learn how you can access his research on this high-conviction stock recommendation, along with many of the other disruptive investments his team is tracking, check out his special [Green Zone Fortunes presentation here.]( [Michael Carr signature] Michael Carr Chief Market Technician, Money & Markets --------------------------------------------------------------- Check Out More From Stock Power Daily: - [DON’T INVEST IN THE “BLACK FRIDAY TRAP”]( - [AI’S NEXT CHALLENGE + HOW 2 STOCKS RATE]( - [2 BLACK FRIDAY STOCKS AREN’T YOUR BEST BUYS]( Privacy Policy The Money & Markets, P.O. Box 8378, Delray Beach, FL 33482. To ensure that you receive future issues of Money & Markets, please add info@mb.moneyandmarkets.com to your address book or [whitelist]( within your spam settings. For customer service questions or issues, please contact us for assistance. The mailbox associated with this email address is not monitored, so please do not reply. Your feedback is very important to us so if you would like to contact us with a question or comment, please click here: [( Legal Notice: This work is based on what we've learned as financial journalists. It may contain errors and you should not base investment decisions solely on what you read here. It's your money and your responsibility. Nothing herein should be considered personalized investment advice. Although our employees may answer general customer service questions, they are not licensed to address your particular investment situation. Our track record is based on hypothetical results and may not reflect the same results as actual trades. Likewise, past performance is no guarantee of future returns. Certain investments carry large potential rewards but also large potential risk. Don't trade in these markets with money you can't afford to lose. Money & Markets permits editors of a publication to recommend a security to subscribers that they own themselves. However, in no circumstance may an editor sell a security before our subscribers have a fair opportunity to exit. Any exit after a buy recommendation is made and prior to issuing a sell notification is forbidden. The length of time an editor must wait after subscribers have been advised to exit a play depends on the type of publication. (c) 2023 Money & Markets, LLC. All Rights Reserved. Protected by copyright laws of the United States and treaties. This Newsletter may only be used pursuant to the subscription agreement. Any reproduction, copying, or redistribution, (electronic or otherwise) in whole or in part, is strictly prohibited without the express written permission of Money & Markets. P.O. Box 8378, Delray Beach, FL 33482. (TEL: 800-684-8471) Remove your email from this list: [Click here to Unsubscribe](